Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Core Insights - Biomea Fusion, Inc. has completed enrollment for the first three dose expansion arms of the COVALENT-111 study, with over 260 type 2 diabetes patients participating [1][4] Study Overview - COVALENT-111 is a multi-site, randomized, double-blind, placebo-controlled Phase I/II clinical trial focusing on type 2 diabetes patients who are uncontrolled by standard care [2][5] - The Phase II portion includes multiple dose escalation and expansion cohorts, evaluating the drug BMF-219 over varying durations and dosages [2][5] Drug Efficacy - Initial results from the dose escalation phase indicate that many participants achieved durable glycemic control after just 4 weeks of BMF-219 treatment, with follow-up extending to 26 weeks [4] - BMF-219 is noted for its unique mechanism of addressing the root cause of diabetes by promoting the proliferation of failing beta cells [4] Future Plans - The company plans to present topline data from the first three expansion arms of COVALENT-111 in Q4 2024, indicating a commitment to ongoing research and development [4]